Investing.comDoubao · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 21:04:42·⟳ 抓取 21:05:17 +35s·⚡ 决策 10-25 21:34:59 +29m42s·2.2 天前
ArriVent公布CDH17靶向ADC药物ARR-217胃肠道肿瘤I期初始数据，Investing.com文章为同一通稿的二手转载
72小时去重命中同一具体催化：2026-10-25 13:04 UTC本臂已基于GlobeNewswire首发通稿对AVBP.US与02157.HK做出ENTER研判；当前Investing.com文章明确标注为AI生成、编辑审核的二手改写，数据点（44.8% ORR、93.1% DCR、安全性、I/1b期推进、2027数据）与首发通稿完全一致，无金额/指引修正/官方新表态等新增事实，按重复消息纪律不再新开仓。
📄 原文Investing.com↗ 原文
ArriVent reports phase 1 data for cancer drug ARR-217
NEWTOWN SQUARE, Pa. - ArriVent BioPharma (NASDAQ:AVBP) announced initial Phase 1 results for ARR-217, an antibody-drug…
不做 ArriVent BioPharma（AVBP.US）
重复消息：同一GlobeNewswire/ESMO 2026通稿已于13:04 UTC首发信号中研判并给出做多腿，本条Investing.com为AI生成二手转载、无新增事实；美股周末闭市，若要交易应以首发信号决策为准，不在转载稿上重复开仓
不做 乐普生物（02157.HK）
同药大中华区权益方，但催化已在首条信号中处理，本条无增量信息；港股已闭市，等待下一交易时段按首发信号逻辑另行判断，不基于重复转载追单
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
ARR-217末线CRC I期数据积极且安全性可控，属正向临床读出，但Investing.com此稿只是约29分钟前已处理的GlobeNewswire/ESMO通稿的AI二手转载，无任何新增事实，重复信号判AVOID，不新增仓位。
消息传播链
- AI生成、编辑审核的二手改写稿，内容与同日GlobeNewswire首发通稿逐点一致，无新增事实；抓取距发布1分钟，但首发信号13:04 UTC已处理
关键理由
- 6mg/kg组末线CRC ORR 44.8%、DCR 93.1%且无ILD/5级TRAE，对核心药受挫后的ArriVent构成平台估值修复催化
- 乐普生物持有大中华区权益（MRG007），存在跨市场情绪传导，但两条腿均已在首发信号中处理
主要风险
- I期样本小、含6例待确认/未确认PR且为单臂数据，2027年前无注册性数据，标题ORR存在回落风险
- 首发于ESMO会议的通稿市场可能已在首条信号窗口定价，二手转载再追入存在高开低走/见光死风险
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-25 · 影响 weakens
44.8% ORR中含4例待确认+2例未确认PR，单臂I期、≥3级TRAE 30.1%，且下一数据点在2027年——属利好中的质量保留项，但已在首发信号中评估，不构成本重复信号的新增交易理由
检索:ARR-217 phase 1 partial responses unconfirmed safety concerns 原文 ↗
先例如何影响了这次决策
对本次决策的影响:未改变结论：本条因NO_INCREMENTAL_FACT判AVOID，无需以先例校准幅度
方向:重复消息早停，未在本条信号上另行检索先例；首发信号已完成研判
涨幅量级:不适用
形态:不适用
工具执行结果 · 成功 3 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 754 ms
{"result": "search_processed_events:agent query=`arr-217 objective response rate gastrointestinal 44.8% | arrivent arr-217 phase 1 data colorectal cancer adc | arrivent biopharma avbp arr-217 lepu biopharma`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 72.0/72 小时、3158 条本臂决策(完整)，返回 1 条候选。\n• 10-25 13:04 UTC(北京 21:04) [b - fetch_decision_experience 成功 stock_tools_inprocess · 3 ms
{ - web_search 成功 doubao_search · 1,513 ms
豆包搜索结果（原始查询:ArriVent ARR-217 Phase 1 results colorectal cancer press release；API SearchType:web）
原文全文
展开原文 · 1,906 字
NEWTOWN SQUARE, Pa. - ArriVent BioPharma (NASDAQ:AVBP) announced initial Phase 1 results for ARR-217, an antibody-drug conjugate developed with Lepu Biopharma Co., Ltd., targeting gastrointestinal malignancies, according to a press release statement.
The multicenter, open-label Phase 1 study evaluated the safety, tolerability, efficacy, and pharmacokinetics of ARR-217 in patients with unresectable, locally advanced, or metastatic solid tumors. As of the August 5, 2026 data cutoff, 123 patients with gastrointestinal malignancies were treated across six dose levels ranging from 2 mg/kg to 8 mg/kg, including 113 patients with colorectal cancer.
At the 6 mg/kg dose administered every three weeks, the study showed a 44.8% objective response rate in pre-treated colorectal cancer patients, comprising seven confirmed partial responses, four partial responses pending confirmation, and two unconfirmed partial responses. The disease control rate at this dose was 93.1%.
At doses of 4 mg/kg and higher, the objective response rate in colorectal cancer patients was 34.2%, with a disease control rate of 91.8%.
The most common treatment-related adverse events were Grade 1/2. Across all doses, 30.1% of patients experienced Grade 3 or higher treatment-related adverse events, including neutropenia at 12.2% and diarrhea at 8.9%. At the 6.0 mg/kg dose, Grade 3 or higher treatment-related adverse events occurred in 20.4% of patients. No grade 5 treatment-related adverse events or interstitial lung disease were observed.
ARR-217 has advanced into Phase 1b dose optimization at doses of 5 and 6 mg/kg, with further data expected in 2027. ArriVent holds exclusive rights to develop and commercialize ARR-217 worldwide outside of Greater China under a collaboration agreement with Lepu Biopharma.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
The multicenter, open-label Phase 1 study evaluated the safety, tolerability, efficacy, and pharmacokinetics of ARR-217 in patients with unresectable, locally advanced, or metastatic solid tumors. As of the August 5, 2026 data cutoff, 123 patients with gastrointestinal malignancies were treated across six dose levels ranging from 2 mg/kg to 8 mg/kg, including 113 patients with colorectal cancer.
At the 6 mg/kg dose administered every three weeks, the study showed a 44.8% objective response rate in pre-treated colorectal cancer patients, comprising seven confirmed partial responses, four partial responses pending confirmation, and two unconfirmed partial responses. The disease control rate at this dose was 93.1%.
At doses of 4 mg/kg and higher, the objective response rate in colorectal cancer patients was 34.2%, with a disease control rate of 91.8%.
The most common treatment-related adverse events were Grade 1/2. Across all doses, 30.1% of patients experienced Grade 3 or higher treatment-related adverse events, including neutropenia at 12.2% and diarrhea at 8.9%. At the 6.0 mg/kg dose, Grade 3 or higher treatment-related adverse events occurred in 20.4% of patients. No grade 5 treatment-related adverse events or interstitial lung disease were observed.
ARR-217 has advanced into Phase 1b dose optimization at doses of 5 and 6 mg/kg, with further data expected in 2027. ArriVent holds exclusive rights to develop and commercialize ARR-217 worldwide outside of Greater China under a collaboration agreement with Lepu Biopharma.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
2cdf41e10a· 2026-10-25 21:34 · doubao / doubao-seed-evolving-latest-version · 策略包b7b4acf827b8当前